Details up front: creatinine · mazdutide.
The empirical answer seems settled. The explanation does not.
If the honest answer is that nobody knows, I would rather hear that than a plausible story.
Why does this happen, and what would falsify the usual explanation?
The short version: enzymes in this class usually fall as weight falls, and a rise is a reason to look for a cause rather than to assume a drug effect.
Reference upper limits around forty units per litre for ALT are conventional rather than physiological; several groups have argued for limits closer to thirty for men and twenty-five for women.
| Trial | Agent | n | Duration | Primary result |
|---|---|---|---|---|
| STEP 1 | Semaglutide 2.4 mg | 1,961 | 68 wk | −14.9 % vs −2.4 % weight |
| STEP 2 | Semaglutide 2.4 mg, T2DM | 1,210 | 68 wk | −9.6 % vs −3.4 % weight |
| SURMOUNT-1 | Tirzepatide 5/10/15 mg | 2,539 | 72 wk | −15 / −19 / −21 % weight |
| SURMOUNT-4 | Tirzepatide, withdrawal | 670 | 88 wk | Continued loss vs substantial regain |
| SELECT | Semaglutide 2.4 mg | 17,604 | ~40 mo | MACE HR 0.80 (0.72–0.90) |
| FLOW | Semaglutide 1.0 mg, CKD | 3,533 | ~3.4 yr | Renal composite reduced; stopped early |
| SURMOUNT-OSA | Tirzepatide, OSA | 469 | 52 wk | AHI reduced with and without PAP |
Specifically, creatine kinase, alkaline phosphatase and bilirubin together tell you which compartment the abnormality is in, and ordering the transaminases alone throws that information away.
Trials in this class have generally reported improvement rather than deterioration in liver biochemistry, consistent with the weight-mediated mechanism.
Isolated mild elevation is common and usually improves with weight loss.
Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.
Shop standardsAnswering this needs the magnitude in multiples of the upper reference limit, because the thresholds that matter clinically are defined that way and not in absolute units.
Gamma-glutamyl transferase is sensitive and unspecific: it rises with alcohol, with several medications and with fatty liver, and an isolated elevation rarely changes anything on its own.
In practice, an isolated result three weeks after starting anything is difficult to interpret. A baseline taken before starting makes the same result trivially interpretable, which is the argument for baselines.
Population data show a substantial fraction of adults with mild transaminase elevation attributable to hepatic steatosis, which sets the base rate against which any new finding should be read.
Transaminases plus bilirubin plus alkaline phosphatase, or you have not measured enough to conclude anything.
The part that matters: this is one of the areas where the trend across several measurements is far more informative than any single result.
Alanine aminotransferase is relatively liver-specific; aspartate aminotransferase is also present in muscle, heart and red cells. A raised AST with a normal ALT after heavy resistance training is usually muscle, and creatine kinase settles the question.
The underlying point is that very rapid weight loss can transiently worsen liver biochemistry, which is one of several arguments against pursuing the steepest possible trajectory.
Laboratory-specific reference intervals for transaminases vary enough that cross-laboratory comparison of borderline values is unreliable.
Nothing here is medical advice. An abnormal result needs somebody who can take a history and examine you.
Read the pattern before the magnitude, and the magnitude in multiples of the upper limit.
edited 15 Jun 2025 by ines_brandt — corrected a unit error in the worked example
The honest answer is that mild elevation is very common, that it usually improves with weight loss, and that the exceptions are the reason anyone checks.
Hy's law describes the combination that matters: transaminases above three times the upper limit together with bilirubin above twice the upper limit and no cholestatic explanation. That combination is a signal; isolated mild transaminase elevation is not.
Hy's law and its variants are the standard framework for identifying drug-induced liver injury in trials and are why bilirubin is measured alongside transaminases rather than instead.
Get a baseline before you start anything, because it converts an uninterpretable result into an interpretable one for the cost of one blood draw.
Start with the pattern. A hepatocellular pattern with alanine aminotransferase above aspartate aminotransferase points one way; a cholestatic pattern with alkaline phosphatase and gamma-glutamyl transferase points another.
Weight loss of ten per cent or more typically reduces transaminases substantially in people whose elevation was driven by hepatic fat, which is the majority of mild elevations in this population.
SELECT reported a hazard ratio of 0.80 (95% CI 0.72–0.90) for the primary composite major adverse cardiovascular event endpoint with semaglutide 2.4 mg in overweight or obese adults with established cardiovascular disease and without diabetes[1].
Research-use material of unknown content is an unquantifiable variable in any such attribution.
New training, alcohol and over-the-counter products first. Then the interesting hypotheses.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.